Efficacy of risperidone in children with disruptive behavioural disorders

Journal of Paediatrics and Child Health

Volumn 49, Issue 1, 2013, Pages 19-26

  Duhig, Michael J ^a   Saha, Sukanta ^a   Scott, James G ^a,b  

^a QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

adolescents; children; disruptive behavioural disorders; efficacy; risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

ABDOMINAL PAIN; ABERRANT BEHAVIOR CHECKLIST; AGITATION; CHILD BEHAVIOR CHECKLIST; CLINICAL GLOBAL IMPRESSION SCALE; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG ERUPTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HYPERPROLACTINEMIA; NAUSEA; NISONGER CHILD BEHAVIOR RATING SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; HUMANS; PSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84872500063     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02200.x     Document Type: Review

References (44)

1. Olfson M, Blanco C, Liu LX, Moreno C, Laje G,. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry 2006; 63: 679-85.
2. Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P,. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin. Ther. 2002; 24: 1466-76.
3. Ashcroft DM, Frischer M, Lockett J, Chapman SR,. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol. Drug Saf. 2002; 11: 285-9.
4. Clavenna A, Rossi E, DeRosa M, Bonati M,. Use of psychotropic medications in Italian children and adolescents. Eur. J. Pediatr. 2007; 166: 339-47.
5. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA,. New users of antipsychotic medications among children enrolled in TennCare. Arch. Pediatr. Adolesc. Med. 2004; 158: 753-9.
6. Toren P, Ratner S, Laor N, Weizman A,. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf. 2004; 27: 1135-56.
7. Chavez B, Chavez-Brown M, Rey JA,. Role of risperidone in children with autism spectrum disorder. Ann. Pharmacother. 2006; 40: 909-16.
8. Haas M, DelBello MP, Pandina G, et al,. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009; 11: 687-700.
9. Elberling H, Linneberg A, Olsen EM, Goodman R, Skovgaard AM,. The prevalence of SDQ-measured mental health problems at age 5-7 years and identification of predictors from birth to preschool age in a Danish birth cohort: the Copenhagen Child Cohort 2000. Eur. Child Adolesc. Psychiatry 2010; 19: 725-35.
10. Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, Koretz DS,. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics 2010; 125: 75-81.
11. Sawyer MG, Arney FM, Baghurst PA, et al,. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Aust. N. Z. J. Psychiatry 2001; 35: 806-14.
12. Achenbach TM, ed. Manuel for the Child Behavior Checklist/4-18 and 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry, 1991.
13. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK,. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73.
14. Ipser J, Stein DJ,. Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology (Berl) 2007; 191: 127-40.
15. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL,. A double-blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 2000; 39: 509-16.
16. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CTM,. A randomized control trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J. Clin. Psychiatry 2001; 62: 239-48.
17. Thompson A, Maltezos S, Paliokosta E, Xenitidis K,. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Cochrane Database Syst. Rev. 2009; 1: 20.
18. Therapeutic Goods Administration. Risperidone public summary document. Department of Health and Ageing, Editor. Canberra, 2005.
19. Correll CU,. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J. Am. Acad. Child Adolesc. Psychiatry 2008; 47: 9-20.
20. Aman MG, Binder C, Turgay A,. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J. Child Adolesc. Psychopharmacol. 2004; 14: 243-54.
21. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL,. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry 2002; 159: 1337-46.
22. Snyder R, Turgay A, Aman M, et al,. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry 2002; 41: 1026-36.
23. Aman MG, Hollway JA, Leone S, et al,. Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Res. Dev. Disabil. 2009; 30: 386-96.
24. Jadad AR, Moore A, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 1996; 17: 12.
25. Guy W, ed. Clinical Global Impressions. Rockville, MD: National Institute of Mental Health, 1976.
26. Aman MG, Singh NN, Stewart AW, Field CJ,. The aberrant behavior checklist-a behavior rating-scale for the assessment of treatment effects. Am. J. Ment. Defic. 1985; 89: 485-91.
27. Aman MG, Tasse MJ, Rojahn J, Hammer D,. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res. Dev. Disabil. 1996; 17: 41-57.
28. Armenteros JL, Lewis JE, Davalos M,. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 558-65.
29. Van Bellinghen M, De Troch C,. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J. Child Adolesc. Psychopharmacol. 2001; 11: 5-13.
30. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M,. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am. J. Psychiatry 2006; 163: 402-10.
31. Tasse MJ, Aman MG, Hammer D, Rojahn J,. The Nisonger Child Behavior Rating Form: age and gender effects and norms. Res. Dev. Disabil. 1996; 17: 59-75.
32. Marshburn EC, Aman MG,. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J. Autism Dev. Disord. 1992; 22: 357-73.
33. Bor W, McGee TR, Fagan AA,. Early risk factors for adolescent antisocial behaviour: an Australian longitudinal study. Aust. N. Z. J. Psychiatry 2004; 38: 365-72.
34. McIntyre RS, Jerrell JM,. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch. Pediatr. Adolesc. Med. 2008; 162: 929-35.
35. Ray WA, Chung CP, Murray KT, Hall K, Stein CM,. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009; 360: 225-35.
36. Correll CU,. Effect of hyperprolactinemia during development in children and adolescents. J. Clin. Psychiatry 2008; 69: e24.
37. Saito E, Correll CU, Gallelli K, et al,. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J. Child Adolesc. Psychopharmacol. 2004; 14: 350-8.
38. Scott S, Sylva K, Doolan M, et al,. Randomised controlled trial of parent groups for child antisocial behaviour targeting multiple risk factors: the SPOKES project. J. Child Psychol. Psychiatry 2010; 51: 48-57.
39. Bywater T, Hutchings J, Daley D, et al,. Long-term effectiveness of a parenting intervention for children at risk of developing conduct disorder. Br. J. Psychiatry 2009; 195: 318-24.
40. Drugli MB, Larsson B, Fossum S, Morch WT,. Five- to six-year outcome and its prediction for children with ODD/CD treated with parent training. J. Child Psychol. Psychiatry 2010; 51: 559-66.
41. Sanders MR, Bor W, Morawska A,. Maintenance of treatment gains: a comparison of enhanced, standard, and self-directed triple P-positive parenting program. J. Abnorm. Child Psychol. 2007; 35: 983-98.
42. Connell AM, Dishion TJ, Yasui M, Kavanagh K,. An adaptive approach to family intervention: linking engagement in family-centered intervention to reductions in adolescent problem behavior. J. Consult. Clin. Psychol. 2007; 75: 568-79.
43. Henggeler SW, Schoenwalk SK, Borduin CM, Rowland MD, Cunningham PB, eds. Multisystemic Treatment of Antosocial Behavior in Children and Adolescents. New York: Guilford, 1998.
44. Bayer J, Hiscock H, Scalzo K, et al,. Systematic review of preventive interventions for children's mental health: what would work in Australian contexts? Aust. N. Z. J. Psychiatry 2009; 43: 695-710.